

International Consortium for Harmonization of Clinical Laboratory Results
Harmonization Oversight Group / Council Conference Call Meeting

DATE: 5 April 2017

TIME: 7:00 a.m. to 8:00 a.m. EDT

HOG Members:

Dr. Greg Miller (Chair)
Dr. Eunice Lee (Vice-Chair)
Mr. Joseph Passarelli
Dr. Naotaka Hamasaki
Dr. Steve Master
Dr. Amy Saenger
Dr. Ian Young

ICHCLR Council Members:

Dr. Gary Myers (chair)
Mr. Hirofumi Koide
Dr. Katsuyuki Nakajima
Dr. Hideo Kato
Dr. Masato Maekawa

HOG Member Absent:

Dr. Tony Killeen

Council Member Absent:

Dr. Junghan Song

AACC Staff:

Ms. Stefanie Kleinman (Scientific and Practice Affairs Specialist)

Minutes:

1. The new web site went live on March 3, 2017. We can now make updates to the measurand table shortly after meetings.
2. The IFCC review group report regarding future collaboration with ICHCLR is expected to be complete in April. Feedback from the IFCC Executive Board is anticipated in June. We will respond according to the feedback received.
3. The Strategic Partners Update was posted to the new web site on March 3, 2017 and circulated to members on March 7, 2017.
4. Gary will gather information from other organizations on work in progress to post and link to the web site.
5. Measurand harmonization status assignments from the last meeting were reviewed, prioritizations agreed, and additional follow-up assigned as shown below.
6. Next call June 1 at 7-8 AM USA Eastern Daylight time (GMT-4)

7. Next face to face meeting July 31 in San Diego during the AACC Annual Meeting

Follow up assignments:

Measurand	Decision	Assigned to
Anti-HCV Ab	Low priority	Steve will write a consolidated justification paragraph
HIV-RNA	Medium priority	Tony will write a consolidated justification paragraph
Folate	Medium priority	Gary will write a consolidated justification paragraph
Protein S	H for Asian population; M other areas; decision needed	Steve: Protein S, per my colleague, has significant variation and would benefit from harmonization in the same way that other coag tests have already benefitted. It looks like the scientific and standardization committee of ISTH already has a committee looking into this, so I'll see if I can contact them for further information.
CO2		Greg has crossover data with 4 mmol/L constant bias. Steve to review crossover data.

Measurand	Decision	Assigned to
D-Dimer		Steve to review PT data; local RI are commonly used; Ian to investigate UK guidelines
Tacrolimus		Ian to review
HCV RNA	H in Japan	Eunice will review status
HCG	Need decision; may be medical use related.	Steve provided a summary (5 pages, 27 references, from Ann Gronowski. Can it be consolidated?
CMV DNA quant	M recommended	Greg received information from Angie Caliendo and will rewrite as a consolidated summary
Vancomycin		Amy will write a consolidated justification paragraph
Ethyl alcohol	Adequate; posted	Greg reviewed literature and PT data that suggests good agreement among methods

Measurand	Decision	Assigned to
Various drugs		Greg got feedback from Paul Janetto and Bill Clarke. Generally adequate agreement but some improvement desirable. Greg will ask a colleague to review comments and recommend a relative priority.
methemoglobin	H	Eunice will write a consolidated justification paragraph
EBV DNA quant	Uncertain	Gary and Tony to follow up
T.pallidum	Adequate; posted	Recommendation from two microbiology/immunology colleagues of Greg
fibrin/fibrinogen degradation products		Tony to ask Chuck Eby at Wash U
rheumatoid factor		Tony to review literature
T3 free	Medium	Greg will write a consolidated justification paragraph
PSA		Steve add to current justification at low values as a trigger for treatment; posted to web site
c-peptide	Work in progress	Amy will write a consolidated justification paragraph

Measurand	Decision	Assigned to
insulin	Work in progress	Amy will write a consolidated justification paragraph